AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS Cancer
Research from University of Louvain has provided new information about HIV/AIDS cancer
July 6th, 2009
According to a study from Louvain, Belgium, "AMD3100 was found to inhibit HIV-1 and HIV-2 within the 1-10 nM concentration range while not being toxic to the host cells at concentrations up to 500 mc M, thus achieving a selectivity index of approximately 100,000. The target of action was initially thought to be the viral envelope glycoprotein gp120." "It appeared only to be the indirect target. The direct target of action turned out to be the co-receptor CXCR4 used by T-lymphotropic HIV strains (now referred to as X4 strains) to enter the cells. Initial (phase I) clinical trials undertaken with AMD3100, as a prelude to its development as a candidate anti-HIV drug for...
Source: AIDS Weekly (2009-07-06)
|
